Otsuka Yasuyuki, Nishikori Momoko, Kitano Toshiyuki, Oka Tomomi, Ishikawa Takayuki, Haga Hironori, Takaori-Kondo Akifumi
Department of Hematology and Oncology Graduate School of Medicine Kyoto University Kyoto Japan.
Department of Hematology Kobe City Medical Center General Hospital Kobe Japan.
Clin Case Rep. 2017 Mar 2;5(4):477-481. doi: 10.1002/ccr3.872. eCollection 2017 Apr.
We report here a patient with extremely indolent mantle cell lymphoma (MCL) who had progressed and required immunochemotherapy 20 years after diagnostic splenectomy. Non-nodal, indolent MCL patients may progress after such an extraordinary long indolent phase, and we recommend lifelong follow up for such cases.
我们在此报告一例惰性程度极高的套细胞淋巴瘤(MCL)患者,该患者在诊断性脾切除术后20年病情进展,需要进行免疫化疗。非淋巴结性、惰性MCL患者在经历如此超长的惰性期后可能会病情进展,对于此类病例我们建议进行终身随访。